2Zeeca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic an emia in children. Blood,2003;101:3857-3861.
3El-Hallak M, Binstadt BA, Leichtner AM, et al. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr, 2007 ; 150(4) :376-382.
4Brandstrup P, SjeiTum OW, Nielsen OJ, et al. Rittuximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thmmboeyt0penie purpura. Am J Hematol, 2005 ;78 (4) : 275 -280.
5Wang J, Wiley JM, Luddy R, et al. Chronic immunethrom bocytopenic purpura in children: assessment of rituximab treatment. J Pediatr, 2005 ;146(2) :217-221.
6Taube T, Schmid H, Reinhard H, et al. Effect of a single dose of rituximab in chronic immtme throm bocytopenic purpura in childhood. Haematologica, 2005 ;90 ( 2 ) : 281-283.
7Okur FV, Oguz A, Karadeniz C, et al. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma. Pediatr Hematol Oncol, 2006 ; 23 ( 1 ) :25-31.
8Imamura T, Yoshihara T, Morimoto A, et al. Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma. Pediatr Hematol Oneol, 2006;23( 1 ) :19-24.
9Bay A, Dogan M, Acikgoz M, et al, Rituximab in a child with relapsed Burkitt lymphoma. Pediatr Blood Cancer, 2007; 49 (2) :218.
10Kraal K, Schalij-Delfos N, van Buchem M, et al. Optic nerve relapse in a child with common acute lymphoblastic leukemia, treated with systemic anti-CD-20 (rituximab). Haematologica, 2005 ;90 :ECR24.
